BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MoneyLion Inc. (NYSE - ML), Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS), Better Choice Inc. (NYSE American - BTTR), NeueHealth, Inc. (NYSE - NEUE)BALA CYNWYD, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRNS, VCSA, MHLD on Behalf of ShareholdersNEW YORK, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Shareholder Alert: Ademi LLP Investigates Whether Marinus Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Ademi LLP is investigating Marinus (Nasdaq: MRNS) for possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica.
MRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Marinus Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Marinus Pharmaceuticals, Inc. (
NASDAQMRNS) to Immedica Pharma AB for $0.55 per share is fair to Marinus shareholders.
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they have entered into an agreement and plan of merger under which Immedica has agreed to acquire Marinus, by means of a tender offer and subsequent merger.
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024.
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency. While reductions in seizure frequency favored the ganaxolone arm, the primary endpoint did not achieve statistical significance.
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented new data from the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) at the Neurocritical Care Society (NCS) Annual Meeting. Topline data demonstrating that the trial met one of two co-primary endpoints were reported in June 2024.
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has added to its intellectual property (IP) estate with a new patent issued by the United States Patent and Trademark Office (USPTO) for ZTALMY® (ganaxolone) oral titration regimens covering the treatment of a range of epilepsy disorders, including CDKL5 deficiency disorder, tuberous sclerosis complex (TSC) and Lennox-Gastaut syndrome (LGS). The U.S. patent No. 12,115,169 expires in September 2042.
3 Micro-Caps Set for Major Moves: Balancing Risk and OpportunityCheck out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success.
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that additional data from the Phase 3 RAISE trial in refractory status epilepticus and retrospective claims-based data from patients with status epilepticus will be presented at the upcoming Neurocritical Care Society (NCS) 22nd Annual Meeting, being held October 14-17 in San Diego, California.
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 9,800 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day and will present an in-depth review of the Company’s development program for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the Phase 3 TrustTSC trial topline data readout anticipated in the first half of the fourth quarter of 2024. The event begins at 9 a.m. ET and will be available via webcast here.
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced agenda topics and speakers for its upcoming Investor & Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. ET in New York.
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:20 a.m. ET.
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an Investor and Analyst Day on Friday, September 20 from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast.
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the second quarter ended June 30, 2024.
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. (“Marinus” or “the Company”) (
NASDAQMRNS) for violations of the securities laws.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Teradata, and Lamb Weston and Encourages Investors to Contact the FirmNEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Marinus Pharmaceuticals, Inc. (
NASDAQMRNS), 2U, Inc.
NASDAQ: TWOUNASDAQTWOU)
(NYSE: TDCNYSETDC
, and Lamb Weston Holdings, Inc. (NYSE: LWNYSE
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (
NASDAQMRNS) securities between March 17, 2021 and May 7, 2024, inclusive (the “Class Period”).
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. (“Marinus” or “the Company”) (
NASDAQMRNS) for violations of the securities laws.
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MarinusFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. (“Marinus” or “the Company”) (
NASDAQMRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
